Lifecore Biomedical (NASDAQ:LFCR) Announces Earnings Results

Lifecore Biomedical (NASDAQ:LFCR) announced its earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.02, Zacks reports. Lifecore Biomedical had a net margin of 5.09% and a negative return on equity of 382.65%.

Lifecore Biomedical Price Performance

LFCR stock opened at $6.66 on Friday. The company has a debt-to-equity ratio of 12.90, a quick ratio of 0.80 and a current ratio of 1.83. The firm has a market cap of $245.27 million, a P/E ratio of 83.25 and a beta of 0.99. The firm’s fifty day moving average is $6.98 and its 200 day moving average is $5.77. Lifecore Biomedical has a 52 week low of $3.68 and a 52 week high of $8.90.

Analyst Upgrades and Downgrades

Separately, Craig Hallum raised their price objective on Lifecore Biomedical from $8.00 to $10.00 and gave the company a “buy” rating in a report on Friday, November 22nd.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.